Zacks Research Has Positive Forecast for RDY Q4 Earnings

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Investment analysts at Zacks Research raised their Q4 2026 earnings per share estimates for shares of Dr. Reddy’s Laboratories in a research note issued to investors on Monday, March 17th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.20 per share for the quarter, up from their previous forecast of $0.19. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $0.80 per share.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%.

RDY has been the subject of several other research reports. StockNews.com downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th. Nomura lowered Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th.

Dr. Reddy’s Laboratories Trading Up 1.1 %

Shares of RDY opened at $13.59 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. Dr. Reddy’s Laboratories has a 1-year low of $12.50 and a 1-year high of $16.89. The stock has a market cap of $11.34 billion, a price-to-earnings ratio of 21.63 and a beta of 0.48. The firm has a 50 day simple moving average of $13.69 and a 200-day simple moving average of $14.73.

Institutional Trading of Dr. Reddy’s Laboratories

Several hedge funds and other institutional investors have recently bought and sold shares of RDY. OneDigital Investment Advisors LLC acquired a new stake in shares of Dr. Reddy’s Laboratories during the third quarter worth $277,000. Natixis Advisors LLC boosted its stake in Dr. Reddy’s Laboratories by 7.2% in the 3rd quarter. Natixis Advisors LLC now owns 10,937 shares of the company’s stock worth $869,000 after buying an additional 735 shares during the last quarter. Caprock Group LLC grew its holdings in Dr. Reddy’s Laboratories by 17.7% in the 3rd quarter. Caprock Group LLC now owns 15,398 shares of the company’s stock valued at $1,223,000 after buying an additional 2,318 shares during the period. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in shares of Dr. Reddy’s Laboratories during the 3rd quarter valued at about $1,997,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Dr. Reddy’s Laboratories by 219.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 155,481 shares of the company’s stock worth $12,353,000 after acquiring an additional 106,796 shares during the period. 3.85% of the stock is owned by hedge funds and other institutional investors.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.